1. Demographic and baseline clinical characteristics (N=79).
| Parameter | Participants
[n (%)] |
| ECOG, Eastern Cooperative Oncology Group; BRCA, breast cancer susceptibility gene; OC, ovarian cancer; BC, breast cancer; *, chemotherapies were for advanced disease. | |
| Sex | |
| Female | 67 (84.8) |
| Male | 12 (15.2) |
| Age (year) [median (range)] | 53 (30−68) |
| ECOG scores | |
| 0 | 58 (73.4) |
| 1 | 21 (26.6) |
| Cancer type | |
| Ovarian | 47 (59.5) |
| Breast | 16 (20.3) |
| Colorectal | 8 (10.1) |
| Esophageal | 1 (1.3) |
| Fallopian tube | 1 (1.3) |
| Gastric | 4 (5.1) |
| Pancreatic | 2 (2.5) |
| BRCA status in patients with OC (n=43) | |
| BRCA mutation | 11 (25.6) |
| BRCA non-mutation | 31 (72.1) |
| Unknown | 1 (2.3) |
| BRCA status in patients with BC (n=16) | |
| BRCAmutation | 2 (12.5) |
| BRCA non-mutation | 14 (87.5) |
| Number of prior chemotherapies* (n=77) | |
| 1 prior chemotherapy | 9 (11.4) |
| 2 prior chemotherapy | 16 (20.3) |
| ≥3 prior chemotherapy | 52 (65.8) |
| Endocrine therapy for patients with BC (n=16) | |
| Yes | 9 (56.3) |
| No | 7 (43.7) |
| No. of metastasis site | |
| 1 | 12 (15.2) |
| 2 | 24 (30.4) |
| ≥3 | 43 (54.4) |
| Site of metastasis | |
| Visceral disease (liver, lung, spleen) | 48 (60.8) |
| No-visceral disease | 31 (39.2) |